Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price dropped 17.1% during trading on Wednesday . The company traded as low as C$0.28 and last traded at C$0.32. Approximately 605,102 shares changed hands during trading, a decline of 10% from the average daily volume of 669,888 shares. The stock had previously closed at C$0.38.
Hemostemix Stock Down 10.1 %
The stock has a market cap of C$27.01 million, a PE ratio of -15.50 and a beta of 0.20. The stock has a 50-day moving average of C$0.15 and a 200 day moving average of C$0.10.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- 5 discounted opportunities for dividend growth investors
- Nebius Group: Market Overreaction or Real AI Disruption?
- Canada Bond Market Holiday: How to Invest and Trade
- The Best Way to Invest in Gold Is…
- Consumer Discretionary Stocks Explained
- Why Nike Stock Could Be 2025’s Top Comeback Play
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
